Inc to “Hold” from “Buy” and lowered its price target to $31 from $35, over the company’s investment strategy and valuation. While Vertex reported solid quarterly, Stifel noted its plan to accelerate ...

Vertex shares fell 15.4% after the company posted in-line Q4 results but disappointing Q1 2025 guidance. Adjusted earnings ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATEC – Research Report), Vertex ...

Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...

Vertex Pharmaceuticals has been attracting investor attention due to strong recent stock performance. The company's shares ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...

Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...